Ambry Genetics Announces Improved EHR-Integrated Breast Cancer Risk Assessment Solution with Upgraded Tyrer-Cuzick Scoring Approach Incorporating Breast Density

The Ambry CARE Program® brings accurate, personalized breast cancer risk assessments directly into clinical workflows helping direct patients at high risk for breast cancer to seek additional screening

Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ:TEM) and a pioneer in clinical genomic testing, today announced an enhancement to the Ambry CARE Program® (CARE), Ambry's digital platform that streamlines cancer risk assessment and genetic testing workflows. The update integrates breast density into the Tyrer-Cuzick (TC) breast cancer risk score within the electronic health record (EHR), providing clinicians with more precise and personalized risk estimates at the point of care that can guide recommendations for breast cancer screening and risk reduction.

Breast cancer is the most common cancer diagnosed in women.¹ Comprehensive risk assessment is essential to identifying who may benefit from earlier or more intensive screening. ¹ Risk assessment is often incomplete or inconsistently applied. As a result, 93% of women with elevated risk who qualify for breast MRI based on medical and family history never receive one.^2,3

Risk models like TC are designed to help close this gap by identifying patients who qualify for advanced screening. The TC model is among the most widely cited breast cancer risk tools, recommended by organizations such as the American College of Radiology (ACR) to guide screening decisions.⁴ Its accuracy improves as more risk factors are incorporated, with breast density as the most recent addition.⁵ Incorporating breast density can make the difference between an average and elevated risk classification.

CARE strengthens this process by embedding TC scores with breast density directly into the EHR, giving clinicians actionable insight without leaving their workflow. With this enhancement, clinicians can access four TC score options aligned with BI-RADS breast density categories (A–D) and use the most appropriate one for each patient.

This update also helps healthcare organizations move beyond simple compliance with FDA requirements to report and notify patients of their breast density.⁶ CARE embeds this information into the risk assessment process, enabling it to directly guide screening and prevention decisions.

These enhanced scores carry real clinical implications. For patients with a 20% or higher risk, increased screening such as annual breast MRI may be recommended.⁴

"Calculating a Tyrer-Cuzick score and engaging women in discussions about their breast cancer risk, screening, and risk-reduction strategies can be lifesaving. Importantly, incorporating breast density into the model makes the assessment even more powerful, as breast density is a significant factor in understanding an individual's risk for breast cancer. Every woman deserves access to this information, yet integrating risk assessment into busy clinical workflows has remained a major challenge. Digital tools that streamline this process hold enormous promise to expand access and ultimately benefit countless women," said New York- based Melissa Frey, M.D. M.S. Associate Professor, Division of Gynecologic Oncology and Director, Genetics and Personalized Cancer Prevention Program. The goal is simple: ensure patients receive the right interventions, whether through earlier detection or risk reduction.

"Accurately assessing breast cancer risk is key to improving outcomes, but important factors like breast density often get overlooked. By bringing together Tyrer-Cuzick scoring and breast density right in the EHR, CARE shows how Ambry is making it easier for providers to get actionable insights within their workflow, ultimately helping patients get the care they need," said Tom Schoenherr, CEO of Ambry Genetics.

CARE incorporates breast density for more accurate breast cancer risk assessments while also supporting comprehensive hereditary cancer risk evaluation. A recent study published in the Journal of the National Comprehensive Cancer Network demonstrated that CARE interprets NCCN Guidelines® with 99.5% accuracy, reinforcing its reliability as a trusted digital risk assessment tool for both clinicians and patients.⁷

For more information about CARE, please visit ambrygen.com/care.

References

1. Sherman RL, Firth AU, Henley SJ, et al. Annual report to the nation on the status of cancer, featuring state‐level statistics after the onset of the COVID‐19 pandemic. Cancer. 2025;131(9):e35833. https://doi.org/10.1002/cncr.35833
2. Miles R, et al. (2018). https://pmc.ncbi.nlm.nih.gov/articles/PMC6007803/
3. Hill, D. A., et al. (2018). https://doi.org/10.1007/s11606-017-4224-6
4. Monticciolo DL, Newell MS, Moy L, et al. Breast cancer screening for women at higher-than-average risk: updated recommendations from the American College of Radiology. J Am Coll Radiol. 2023. Link
5. Brentnall AR, Cuzick J. Risk Models for Breast Cancer and Their Validation. Stat Sci. 2020 Mar 3;35(1):14-30. doi: 10.1214/19-STS729. PMID: 32226220; PMCID: PMC7100774. https://pmc.ncbi.nlm.nih.gov/articles/PMC7100774/
6. Fecteau H, Pfleger H, Nathan D, et al. Validation of a digital tool that uses national testing guidelines to identify individuals at risk for hereditary cancer. J Natl Compr Canc Netw. 2025;23(8):e257025.https://doi.org/10.6004/jnccn.2025.7025
7. BIS Breast Cancer Risk Evaluation Tool. 2017. Available at: https://ems-trials.org/riskevaluator. Accessed August 19, 2025.

ABOUT TEMPUS

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

FORWARD LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus' industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the potential impact of Ambry Genetics research and publications; the contributions of Ambry Genetics research and findings to the larger scientific community and the use of its products and services to advance clinical care for patients are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "going to," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus' business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus' financial performance; the ability to attract and retain customers and partners; managing Tempus' growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus' intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" in Tempus' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ("SEC") on February 24, 2025, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

ABOUT AMBRY GENETICS ®

Ambry Genetics, a wholly owned subsidiary of Tempus, translates scientific research into clinically actionable test results based upon a deep understanding of the human genome and the biology behind genetic disease. It is a leader in genetic testing and aims to improve health by understanding the relationship between genetics and disease. Over its 25-year history, Ambry has remained committed to empowering patients to make informed healthcare decisions based on their genetic data.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251001225867/en/

MEDIA CONTACT

For Ambry Genetics

[email protected]